Key result
Doxorubicin-induced cardiotoxicity occurred in 11% of patients over 12 months, but no association was observed with SLC28A3, UGT1A6*4, or RARG genetic variants.
Why the study?
Doxorubicin-induced cardiotoxicity is a significant cause of mortality in cancer care, and the predictive power of genetic biomarkers in Zimbabwean breast cancer patients was unknown.
Cohort (n=50)
Supports DIC monitoring in African breast cancer patients; leaves open predictive utility of UGTA1A6*4, SLC28A3 and RARG biomarkers.
AIMS Doxorubicin-induced cardiotoxicity (DIC) is a significant cause of mortality in cancer care. This study was conducted to establish the frequency of DIC in Zimbabwean breast cancer patients on doxorubicin and to test the DIC predictive power of genetic biomarkers. METHODS A cohort of 50 Zimbabwean breast cancer patients treated with doxorubicin were followed up for 12 months with serial echocardiography and genotyped for UGTA1A6*4, SLC28A3 and RARG. 11% of the patients experienced DIC. RESULTS The frequency of SLC28A3 (rs7853758), UGT1A6*4 (rs17863783) and RARG (rs2229774) was 60.7%, 17.9% and 14.3% respectively. No association between DIC and the three variants was observed. CONCLUSIONS This is the first study on the prevalence of DIC and associated genetic biomarker predictive evaluation in Zimbabwean breast cancer patients. The genetic frequencies observed in our study was different to that reported in other populations. A larger sample size with a longer follow up time will be necessary in future studies.
No takes yet. Share an insight, caveat, or question.
Nyangwara et al. (2022) conducted a cohort in Breast cancer (n=50). Doxorubicin treatment and genetic biomarkers (UGT1A6*4, SLC28A3, RARG) was evaluated on Doxorubicin-induced cardiotoxicity (DIC) and association with genetic variants. Doxorubicin-induced cardiotoxicity occurred in 11% of patients over 12 months, but no association was observed with SLC28A3, UGT1A6*4, or RARG genetic variants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: